Author Question: The American College of Cardiology (ACC)/American Heart Association (AHA) published management ... (Read 88 times)

Capo · **on:** Jul 23, 2018

The American College of Cardiology (ACC)/American Heart Association (AHA) published management guidelines for heart failure.

They have defined stage A as including patients with no symptoms or functional cardiac anomalies who have which of the following behaviors or conditions that are strongly associated with developing heart failure?
a. Hypertension, headaches, and schizophrenia
b. Tachycardia, scleroderma, and bipolar disease
c. Treatment with cardiotoxic drugs, hypertension, and diabetes
d. Diabetes, hyperlipidemia, and headaches

Question 2

The nurse is providing patient education about digoxin (Lanoxin) to a 50-year-old woman. Which statement by the patient demonstrates a need for further teaching?

a. I should monitor my heart rate prior to taking this medication.
b. This medication prolongs life in women.
c. I will not see full benefits for 1 to 3 months.
d. This medication can cause electrolyte imbalance, so I will need to have my blood checked periodically.

DylanD1323 · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

ANS: C
Treatment with cardiotoxic drugs (eg, doxorubicin, trastuzumab) combined with hypertension and diabetes correlates with a high risk of the development of heart failure.
Headaches and schizophrenia are not considered high risk for heart failure.
Scleroderma and bipolar disease do not correlate with a high risk for heart failure.
Diabetes, hyperlipidemia, and hypertension are associated with a risk, but not a high risk, for the development of heart failure.

Answer to Question 2

ANS: B
Digoxin actually may shorten the life span in women; this statement indicates that further teaching is required.
The patient should monitor her pulse and heart rate and should withhold the drug if her heart rate is below 60.
The medication will take at least 1 to 3 months to exert its full effects.
The patient will need routine chemistry profiles to monitor electrolyte balance and renal function.